Interneuron Licenses Treatment For Liver Disease

Interneuron Pharmaceuticals, Inc. has exercised its option and entered into an agreement to license IP 501, an orally-administered anti-fibrotic purified phospholipid compound in Phase 3 development for the treatment and prevention of liver diseases, including alcohol and Hepatitis C-induced cirrhosis. The license agreement gives Interneuron rights to develop and commercialise the drug in several major Read more about Interneuron Licenses Treatment For Liver Disease[…]

Positive Results For InKine’s Cbp-1011 In Patients With Crohn’s Disease

InKine Pharmaceutical Company announced positive results of its multicenter open-labeled, clinical trial of CBP-1011 in the treatment of patients with mild or moderate Crohn’s disease. Key results of the study included* 80% of patients who completed the study responded to treatment with CBP-1011 using endpoints that were previously defined by the U.S. Food and Drug Read more about Positive Results For InKine’s Cbp-1011 In Patients With Crohn’s Disease[…]

Eli Lilly And Reliant Announce Sales And Marketing Agreement

Reliant Pharmaceuticals, LLC, and Eli Lilly and Company announced that Lilly would sell to Reliant the sales and marketing rights for the antiulcer agent Axid in the United States (excluding Puerto Rico). This agreement will help maximize future sales of Axid through expanded sales and marketing efforts and the development of additional formulations by Reliant. Read more about Eli Lilly And Reliant Announce Sales And Marketing Agreement[…]

Carrington Announces Results Of Aliminase Clinical

Carrington Laboratories, Inc. announced the results of its Phase III pivotal trial with Aliminase for ulcerative colitis. Indications were that no significant differences were found to support a therapeutic drug effect. In light of these results, the company plans to discontinue the development and testing of Aliminase as a treatment for ulcerative colitis. “Although we Read more about Carrington Announces Results Of Aliminase Clinical[…]

Cellegy Begins Phase III Clinical Trial With Anogesic

Cellegy Pharmaceuticals, Inc., has initiated a second Phase III clinical trial to provide confirmatory evidence that Anogesic (nitroglycerin ointment) reduces the average daily pain associated with anal fissures. Initiation of this trial follows review by the US FDA of the study protocol and the results of a recently completed Phase III trial. In the recently Read more about Cellegy Begins Phase III Clinical Trial With Anogesic[…]